Neoantigen Summit, Boston, November 15-17, 2016
Society of Immunotherapy of Cancer’s Annual Meeting & Associated Programs, National Harbor, November 9-13, 2016
- Genome-Scale Neoantigen Screening Using ATLAS Prioritizes Candidate Antigens for Immunotherapy in a Non-Small Cell Lung Cancer Patient
Society for Immunotherapy of Cancer’s Annual Meeting & Associated Programs in National Harbor, November 7, 2015
Antigen-Screening System - Perfecting the Promise of T Cell Therapies for Infectious Disease & Cancer
Flechtner, JB (2016) Drug Development & Delivery epub June 2016
This article describes Genocea’s proprietary ATLAS™ technology, illustrating how finding the RIGHT targets of T cell responses matters for successful immunotherapies and vaccines. The article describes how ATLAS had yielded an HSV-2 immunotherapy that has shown unprecedented efficacy in Phase 2 clinical trials and then introduces emerging cancer immunotherapy programs that highlight the ways ATLAS is poised to revolutionize immuno-oncology.